Drug Trial Radar · NCT07503444
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 14, 2026
Primary completion
Feb 6, 2029
Study completion Aug 29, 2031
Sponsor
- Lead sponsor
- UCB BIOSCIENCES, Inc.UCB
- Sponsor type
- Industry
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).
Conditions
- Rett Syndrome
Interventions
fenfluramine hydrochlorideDrug
Oral solution
PlaceboOther
Oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total ScoreTime frame: From Baseline (Day 1) to Week 14
- Clinical Global Impression of Change (CGIC) Score at Week 14Time frame: At Week 14
Locations
46 sites in 13 countries. Site status is shown where the registry gives one.
Ep0247 21010
Little Rock, Arkansas · Recruiting
Ep0247 21009
Miami, Florida · Recruiting
Ep0247 21011
Orlando, Florida · Recruiting
Ep0247 21007
Atlanta, Georgia · Recruiting
Ep0247 21003
Philadelphia, Pennsylvania · Recruiting
Ep0247 21005
Houston, Texas · Recruiting
Ep0247 21013
Irving, Texas · Recruiting
Ep0247 21004
Seattle, Washington · Recruiting
Ep0247 11001
Brussels, Belgium · Recruiting
Ep0247 11002
Edegem, Belgium · Recruiting
Ep0247 42001
Beijing, China · Recruiting
Ep0247 42009
Shanghai, China · Recruiting
Ep0247 12005
Brest, France · Recruiting
Ep0247 12003
Bron, France · Recruiting
Ep0247 12004
Marseille, France · Recruiting
Ep0247 12001
Paris, France · Recruiting
Ep0247 12006
Paris, France · Recruiting
Ep0247 13001
Tbilisi, Georgia · Recruiting
Ep0247 13002
Tbilisi, Georgia · Recruiting
Ep0247 14001
Vogtareuth, Germany · Recruiting
Ep0247 15001
Budapest, Hungary · Recruiting
Ep0247 15002
Debrecen, Hungary · Recruiting
Ep0247 16001
Ramat Gan, Israel · Recruiting
Ep0247 17007
Florence, Italy · Recruiting
Ep0247 17003
Genova, Italy · Recruiting
Ep0247 17001
Milan, Italy · Recruiting
Ep0247 17008
Naples, Italy · Recruiting
Ep0247 17002
Pisa, Italy · Recruiting
Ep0247 17009
Roma, Italy · Recruiting
Ep0247 17006
Troina, Italy · Recruiting
Ep0247 43005
Chiyoda-ku, Japan · Recruiting
Ep0247 43004
Kodaira, Japan · Recruiting
Ep0247 43001
Kurume, Japan · Recruiting
Ep0247 43006
Musashimurayama-shi, Japan · Recruiting
Ep0247 43002
Osaka, Japan · Recruiting
Ep0247 43003
Setagaya-ku, Japan · Recruiting
Ep0247 19003
Gdansk, Poland · Recruiting
Ep0247 19002
Krakow, Poland · Recruiting
Ep0247 11106
Barcelona, Spain · Recruiting
Ep0247 11101
Madrid, Spain · Recruiting
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.